Sideris, K., Nelson, T. J., Brinker, L., Gao, A., Tcheandjieu, C., Kyriakopoulos, C. P., … Lynch, J. A. (2025). Risk of Systemic Manifestations in Homozygous Carriers of the Transthyretin V142I Variant: A Million Veteran Program Analysis. Journal of the American Heart Association, 14(23), e044923. https://doi.org/10.1161/jaha.125.044923

Sideris, Konstantinos, Tyler J. Nelson, Lina Brinker, Anthony Gao, Catherine Tcheandjieu, Christos P. Kyriakopoulos, Dan Berlowitz, et al. “Risk of Systemic Manifestations in Homozygous Carriers of the Transthyretin V142I Variant: A Million Veteran Program Analysis.” Journal of the American Heart Association 14, no. 23 (December 2025): e044923. https://doi.org/10.1161/jaha.125.044923.

Sideris K, Nelson TJ, Brinker L, Gao A, Tcheandjieu C, Kyriakopoulos CP, et al. Risk of Systemic Manifestations in Homozygous Carriers of the Transthyretin V142I Variant: A Million Veteran Program Analysis. Journal of the American Heart Association. 2025 Dec;14(23):e044923.

Sideris, Konstantinos, et al. “Risk of Systemic Manifestations in Homozygous Carriers of the Transthyretin V142I Variant: A Million Veteran Program Analysis.” Journal of the American Heart Association, vol. 14, no. 23, Dec. 2025, p. e044923. Epmc, doi:10.1161/jaha.125.044923.

Sideris K, Nelson TJ, Brinker L, Gao A, Tcheandjieu C, Kyriakopoulos CP, Berlowitz D, Hull L, Ferraro JP, Agiri FY, Pridgen KM, Roblin S, Joseph J, Levin MG, Damrauer SM, Chang K-M, Teerlink CC, Stehlik J, Carter S, Lynch JA. Risk of Systemic Manifestations in Homozygous Carriers of the Transthyretin V142I Variant: A Million Veteran Program Analysis. Journal of the American Heart Association. 2025 Dec;14(23):e044923.